Gerry McElvaney
Prof McElvaney has a strong track record in translational research and has published widely in the areas of CF, alpha-1 antitrypsin deficiency (AATD), infection, immunity, and lung inflammation. He is the Director of the Cystic Fibrosis unit in Beaumont Hospital, Dublin, Ireland and has received national and international funding, including grants from the Health Research Board, Science Foundation Ireland, The Higher Education Authority, The CF Association of Ireland, and the US Alpha-1 Foundation. His unit has a well-established track record in research into CF and AATD and their work on lung defenses has led to interactions with pharmaceutical companies interested in translational research. For example, in 1999 Beaumont Hospital was the first site worldwide for intravenous administration of transgenic alpha 1-antitrypsin to individuals with alpha-1 antitrypsin deficiency. 2004 saw the first Phase 1 study in Beaumont Hospital of Lomucin, a medication developed to block abnormal mucin production from bronchial epithelium. This work arose directly from research carried out in the Respiratory Research Division. In 2001 Prof McElvaney founded the Alpha One Foundation of Ireland. Subsequently he received funding from the Department of Health and Children to establish the first targeted detection programme for alpha-1 antitrypsin deficiency in Europe.
